ESPE Yearbook of Paediatric Endocrinology

In Brief: This phase 2 trial randomized 338 adults with overweight or obesity to once-weekly subcutaneous Retatrutide (LY3437943), a ‘triple agonist’ for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP1), and glucagon receptors, or placebo. Mean % change in body weight at 24 weeks was −7.2%, −12.9%, −17.3% and −17.5% in the 1-mg, 4-mg, 8-mg and 12-mg Retatrutide groups, compared with −1.6% in the placebo ...

To read the full abstract: Nat Med 2020;26(4):485–497.More than 100 medical and scientific organizations supported this international consensus statement, which describes impressively how unscientific public narratives of obesity cause weight stigma and stimulates discrimination of obese people. Consequently, the statement calls for strong policies and legislation to prevent weight-bas...